Gen­Fleet high­lights Phase 2 da­ta on KRAS/EGFR com­bo in lung can­cer 

Last year
R&D
China

BMS de­tails con­fir­ma­to­ry tri­al win for KRAS in­hibitor Kraza­ti

Last year
R&D

Mer­ck’s $3B re­turn to eye dis­ease; J&J’s $1.25B tuck-in; Keytru­da chal­lenger steals #AS­CO24 show; and more

Last year
Weekly

Io­vance's TIL ther­a­py plus Keytru­da show durable treat­ment ef­fect in melanoma, but ac­cess re­mains a ques­tion

Last year
R&D
Cell/Gene Tx

Mer­ck CEO says Keytru­da is ‘not a re­peat­able mod­el’

Last year
Pharma

Im­muno­core un­veils ear­ly-stage da­ta of skin can­cer treat­ment that led it to start Phase 3 tri­al

Last year
R&D

FDA ques­tions da­ta on MD­MA-based ther­a­py in PTSD ahead of ad­vi­so­ry com­mit­tee

Last year
Pharma
FDA+

No­var­tis sues Mary­land over state law ban­ning lim­its on dis­counts to 340B con­tract phar­ma­cies

Last year
Pharma
Law

CHMP rec­om­mends 14 new ap­provals, sev­en la­bel ex­pan­sions

Last year
Pharma
FDA+

Drug­mak­ers to Mary­land af­ford­abil­i­ty board: Cap­ping list prices may not help pa­tients

Last year
Pharma
Law

'In­vis­i­ble hand' of in­her­it­ed ge­net­ics can dri­ve can­cer risk, new study sug­gests

Last year
R&D

Joe Jimenez and Mark Fish­man tar­get $400M for third fund af­ter leav­ing No­var­tis

Last year
Financing
Startups

FDA ap­proves Mod­er­na's RSV vac­cine, mark­ing its sec­ond com­mer­cial prod­uct

Last year
Pharma
FDA+

No­var­tis shares up­dat­ed da­ta for BTK in­hibitor; Astel­las re­sub­mits BLA for can­cer drug af­ter CRL

Last year
News Briefing

#AS­CO24: No­var­tis' new CML treat­ment tops old­er drugs, in­clud­ing Gleevec, in Phase 3 tri­al

Last year
R&D
Pharma

#AS­CO24: Gilead presents more da­ta on failed Trodelvy lung can­cer study

Last year
R&D
Pharma

Adap­ti­m­mune taps Gala­pa­gos to de­cen­tral­ize man­u­fac­tur­ing of sol­id tu­mor T cell ther­a­py

Last year
Deals
Cell/Gene Tx

Io­n­is out­lines Phase 3 da­ta for rare dis­ease drug, preps for an­oth­er po­ten­tial launch

Last year
R&D

Neu­ro­crine CEO Kevin Gor­man to re­tire af­ter 32-year run; Blue­bird picks up fifth CFO in three years

Last year
People
Peer Review

Ul­tragenyx touts Phase 3 win for gene ther­a­py in rare glyco­gen stor­age dis­or­der

Last year
R&D
Cell/Gene Tx

FDA de­lays Dupix­ent in COPD de­ci­sion by three months while EMA gives thumbs-up

Last year
FDA+

Gilead’s block­buster ADC Trodelvy fails blad­der can­cer con­fir­ma­to­ry study

Last year
R&D
Pharma

Sum­mit Ther­a­peu­tics touts a rare tri­umph over Keytru­da in lung can­cer from a Chi­na-on­ly Phase 3 study

Last year
R&D

No­vo Nordisk mounts le­gal cam­paign against com­pa­nies mar­ket­ing com­pound­ed semaglu­tide

Last year
Pharma
Law
First page Previous page 149150151152153154155 Next page Last page
A service from the Financial Times